Headquartered in San Diego, CA Fiscal year ends December NASDAQ: RNA atriumtherapeutics.com
Atrium Therapeutics, Inc. (Nasdaq: RNA) is a clinical-stage biopharmaceutical company developing RNA therapeutics delivered specifically to the heart for genetically driven cardiomyopathies.
**Platform**
- Its proprietary technology was designed at Avidity Biosciences, the company's former parent.
- It pairs the tissue selectivity of monoclonal antibodies and other targeting ligands with the precision of oligonucleotides.
- The aim is targeted, non-viral delivery of small interfering RNA (siRNA) to cardiac tissue, building on demonstrated delivery to skeletal muscle.
**Pipeline**
- ATR 1072 for PRKAG2 syndrome: in the Phase 1/2 Corventis trial, with initial proof-of-concept data expected in the second half of 2027.
- ATR 1086 for PLN (phospholamban) cardiomyopathy: IND planned for 2027.
- Two undisclosed research programs in rare cardiomyopathies.
**Revenue**
The company currently earns collaboration revenue under a research collaboration and license agreement with Bristol Myers Squibb, including milestone payments and R&D services. Updated
Pro-forma cash of $293.6 million funds this $128 million market cap company through 2028, past the first Corventis data in the second half of 2027. A $15.0 million Bristol Myers Squibb milestone shrank the quarterly loss to its narrowest in two years, beating expectations on both EPS and revenue.
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Viking Therapeutics.
The release of OpenAI‘s ChatGPT chatbot in November 2022 unleashed a frenzy of investor interest in artificial intelligence that propelled Nvidia (NASDAQ:NVDA | NVDA Price Prediction) to the forefront of the industry.…
Atrium Therapeutics, Inc. (Nasdaq: RNA) is a clinical-stage biopharmaceutical company developing RNA therapeutics delivered specifically to the heart for genetically driven cardiomyopathies. **Platform** - Its proprietary technology was designed at Avidity Biosciences, the company's former parent. - It pairs the…
The Wall Street consensus 12-month price target for RNA is $22.00.
